Savient Pharmaceuticals Pre-Announces Range of KRYSTEXXA Q4 Net Sales of $2.8-3.0M

Savient

today announced that it expects to report that net sales of KRYSTEXXA grew in the fourth quarter to a range of between $2.8 and $3.0 million for the three months ended December 31, 2011, as compared to $1.9 million for the three months ended September 30, 2011.